PRKN and placental insufficiency: Therapies that enhance PINK1–PARK2-mediated mitophagy, whether by pharmacological stimulation or gene therapy, have the potential to selectively remove defective mitochondria while retaining trophoblast function and avoiding placental insufficiency.